Product Description
a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2 (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34822610/)
Mechanisms of Action: AChR Inhibitor
Novel Mechanism: No
Modality: N/A
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: University of Tokushima
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|